CING
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Cingulate Inc. (CING) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B-); its weakest is Profitability (C). The rating has held at C+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C+ (2.5) | B- (2.9) | C (2.5) | B- (2.9) | C+ (2.6) | C+ (2.7) |
| 2026-11-04 | C+ (2.5) | B- (2.9) | C+ (2.6) | B- (2.9) | C+ (2.7) | C+ (2.7) |
| 2026-10-28 | C+ (2.5) | C+ (2.8) | C+ (2.6) | B (3.2) | C+ (2.7) | C+ (2.8) |
| 2026-10-21 | C+ (2.5) | C+ (2.8) | C+ (2.5) | C+ (2.6) | C+ (2.6) | C+ (2.6) |
| 2026-10-14 | C+ (2.5) | C+ (2.8) | C+ (2.5) | B- (2.9) | C+ (2.6) | C+ (2.7) |